Rutgers Cancer Institute of New Jersey: Study Uncovers Triple Immunotherapy Combination As Potential Treatment For Pancreatic Cancer
January 04, 2023
January 04, 2023
NEW BRUNSWICK, New Jersey, Jan. 4 (TNStalk)(TNSjou) -- Rutgers Cancer Institute of New Jersey issued the following Q&A on Jan. 3, 2023, with Prateek Gulhati, physician-scientist in the Gastrointestinal Oncology Program:
* * *
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with poor prognosis and limited treatment options.
Researchers from Rutgers Cancer Institute of New Jersey, the state's leading cancer program and only National . . .
* * *
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with poor prognosis and limited treatment options.
Researchers from Rutgers Cancer Institute of New Jersey, the state's leading cancer program and only National . . .